Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 2/20 | 0.43 |
| ▸ | PCNA | P12004 | 4/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | THRA | P10827 | 2/20 | 0.42 |
| ▸ | THRB | P10828 | 2/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.38 |
| ▸ | PSMB8 | P28062 | 2/20 | 0.36 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.36 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | PGR | P06401 | 1/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.36 |
| ▸ | HTR1A | P08908 | 1/20 | 0.36 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.36 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.36 |
| ▸ | AR | P10275 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7525080 | 0.88 | APP (0.56) | APPHIF1AMAPK1LMNAHTR1A | |
| SCHEMBL11258106 | 0.84 | APP (0.43) | APPPSMB8PSMB5IAPPALOX5 | |
| SCHEMBL4290267 | 0.84 | APP (0.43) | APPTHRATHRBFFAR1PSMB8 | |
| SCHEMBL11939898 | 0.84 | APP (0.43) | APPPSMB8PSMB5CYP1A2CYP2C9 | |
| SCHEMBL23048320 | 0.84 | ALDH1A1 (0.46) | APPPSMB8PSMB5IAPPALOX5 | |
| SCHEMBL19658184 | 0.83 | TDP1 (0.42) | APPFFAR1PSMB8PSMB5 | |
| SCHEMBL7525396 | 0.82 | ALOX5 (0.58) | POLBMAPK1LMNACYP1A2HTR1A | |
| SCHEMBL8948701 | 0.82 | PSMB8 (0.37) | APPPSMB8PSMB5HTR2A | |
| SCHEMBL112099 | 0.80 | FAAH (0.41) | APPPOLBTHRBMAPK1PSMB8 | |
| SCHEMBL17767816 | 0.80 | PSMB8 (0.42) | APPMAPK1PSMB8PSMB5HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4379725-A2 | IMMUNE RECOGNITION MOTIFS | Iogenetics, LLC. (US) | 2024-06-05 | — | — | EP | disclosed |
| EP-3167396-B1 | IMMUNE RECOGNITION MOTIFS | IOGENETICS LLC (US) | 2024-01-17 | — | — | EP | disclosed |
| US-20200402615-A1 | IMMUNE RECOGNITION MOTIFS | IOGENETICS, LLC | 2020-12-24 | — | — | US | disclosed |
| US-10755801-B2 | Identifying peptides having T-cell-exposed motifs with known frequency of occurrence in a reference database | IOGENETICS, LLC (US) | 2020-08-25 | — | — | US | disclosed |
| US-20170161430-A1 | IMMUNE RECOGNITION MOTIFS | IOGENETICS LLC (US) | 2017-06-08 | — | — | US | disclosed |
| EP-3167396-A2 | IMMUNE RECOGNITION MOTIFS | Iogenetics, LLC. (US) | 2017-05-17 | — | — | EP | disclosed |
| US-20110280803-A1 | RADIOIODINATION METHOD | GE HEALTHCARE UK LIMITED (GB) | 2011-11-17 | — | — | US | disclosed |
| US-20110280803-A1 | RADIOIODINATION METHOD | GE HEALTHCARE UK LIMITED (GB) | 2011-11-17 | — | — | US | disclosed |
| EP-1298439-B1 | METHOD FOR SCREENING MCH RECEPTOR ANTAGONIST/AGONIST | TAKEDA PHARMACEUTICAL (JP) | 2010-11-24 | — | — | EP | disclosed |
| WO-2010086398-A1 | RADIOIODINATION METHOD | GE HEALTHCARE LIMITED (GB) | 2010-08-05 | — | — | WO | disclosed |
| EP-1143000-A1 | SCREENING METHOD | Takeda Chemical Industries, Ltd. (JP) | 2001-10-10 | — | — | EP | disclosed |
| EP-1024838-A1 | STABLE RADIOIODINE CONJUGATES AND METHODS FOR THEIR SYNTHESIS | Immunomedics, Inc. (US) | 2000-08-09 | — | — | EP | disclosed |
| WO-1999011294-A1 | STABLE RADIOIODINE CONJUGATES AND METHODS FOR THEIR SYNTHESIS | IMMUNOMEDICS, INC. (US) | 1999-03-11 | — | — | WO | disclosed |
| US-5270302-A | Derivatives of tetrapeptides as CCK agonists | ABBOTT LABORATORIES (US) | 1993-12-14 | — | — | US | disclosed |
| US-5242680-A | Diagnostic and therapeutic | MERCK & CO., INC. (US) | 1993-09-07 | — | — | US | disclosed |
| EP-0524722-A1 | Thiol-reactive maleimido-based radiolabeling reagents | MERCK & CO. INC. (US) | 1993-01-27 | — | — | EP | disclosed |
| WO-1991019733-A1 | DERIVATIVES OF TETRAPEPTIDES AS CCK AGONISTS | ABBOTT LABORATORIES (US) | 1991-12-26 | — | — | WO | disclosed |
| EP-0232348-A1 | HOMOGENEOUS PROCESS FOR THE LUMINESCENT DETERMINATION AND/OR DETECTION OF AN ANALYTE IN A MEDIUM SUSCEPTIBLE OF CONTAINING IT. | COMMISSARIAT ENERGIE ATOMIQUE (FR) | 1987-08-19 | — | — | EP | disclosed |
| WO-1987000927-A1 | HOMOGENEOUS PROCESS FOR THE LUMINESCENT DETERMINATION AND/OR DETECTION OF AN ANALYTE IN A MEDIUM SUSCEPTIBLE OF CONTAINING IT | COMMISSARIAT A L'ENERGIE ATOMIQUE (FR) | 1987-02-12 | — | — | WO | disclosed |
| WO-1985000169-A1 | 1,4-DIHYDROPYRIDINE DERIVATIVES, PRODUCTION THEREOF AND PHARMACEUTICAL PREPARATIONS CONTAINING THEM | SANDOZ AG (CH) | 1985-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110280803-A1 | RADIOIODINATION METHOD | TPO, SSTR5, DAO | APP 2661/4885PCNA 987/4885POLB 1262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.